InnoCare Pharma (FRA:33C) Interest Expense : €-2.55 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InnoCare Pharma's interest expense for the three months ended in Dec. 2023 was € 0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.55 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InnoCare Pharma's Operating Income for the three months ended in Dec. 2023 was € -17.28 Mil. InnoCare Pharma's Interest Expense for the three months ended in Dec. 2023 was € 0.11 Mil. InnoCare Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InnoCare Pharma Interest Expense Historical Data

The historical data trend for InnoCare Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Interest Expense Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.12

-0.14

-0.37

-2.31

-4.50

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial												39.93	-	-2.00	0.11	-0.66

InnoCare Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.55 Mil.

InnoCare Pharma (FRA:33C) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InnoCare Pharma's Interest Expense for the three months ended in Dec. 2023 was €0.11 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-17.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €8.98 Mil.

InnoCare Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines